JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating

With significant upside potential, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) secures a spot on our list of the best small-cap biotech stocks to buy according to analysts.

JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating

On November 12, 2025, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) saw JPMorgan reduce its price target from $40 to $33, while reiterating its “Overweight” rating. The price target adjustment reflects the investment firm’s revisions to its models in the SMID-cap biotechnology group, as reported by The Fly.

Meanwhile, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) reported Q3 results on November 3, 2025. The quarter saw a 21% increase in total revenue to $45.9 million, reflecting strong uptake of its lead therapies. In particular, Revuforj was included in NCCN guidelines and received FDA approval for a broader patient population, contributing significantly to the company’s sustained growth. Meanwhile, Niktimvo recorded $200 million in annualized revenue.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) ended the quarter with $456 million in cash balances, sufficient to support its ongoing operations and pipeline development through to profitability. The company’s net loss narrowed to $60.7 million, or $0.70 per share, compared to $84.1 million, or $0.98 per share, in Q3 2024. Looking ahead, the company projected total R&D costs of $380 to $385 million for the full year.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a biopharmaceutical company that develops and commercializes targeted therapies for rare and difficult-to-treat cancers.

While we acknowledge the potential of SNDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SNDX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.